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Single photon emission CTMethods: Patients (men 45 years; women 50 years) with known or suspected coronary
artery disease (n ¼ 124) were randomized to 1 of 2 diagnostic sequences: rest and rega-
denoson SPECT on day 1, then regadenoson CTP and rest CTP (and coronary CT angiog-
raphy [CTA]) (CTA; same acquisition) on day 2 or regadenoson CTP and rest CTP (and CTA)
on Day 1, then rest and regadenoson SPECT on day 2. Scanning platforms included 64-, 128-
, 256-, and 320-slice systems. The primary analysis examined the agreement rate between
CTP and SPECT for detecting or excluding reversible ischemia in 2 myocardial segments
as assessed by independent, blinded readers.
Results: Complete and interpretable CTP and SPECT scans were obtained for 110 patients.
Regadenoson CTP was noninferior to SPECT for detecting or excluding reversible ischemia
with an agreement rate of 0.87 (95% confidence interval [CI], 0.77e0.97) and sensitivity and
specificity of 0.90 (95% CI, 0.71e1.00) and 0.84 (95% CI, 0.77e0.91), respectively. The agree-
ment rate for detecting or excluding 1 fixed defects by regadenoson CTP and SPECT was
0.86 (95% CI, 0.74e0.98). With SPECT as the reference standard, the diagnostic accuracies
for detecting or excluding ischemia by regadenoson CTP and CTA alone were 0.85 (95% CI,
0.78e0.91) and 0.69 (95% CI, 0.60e0.77), respectively.
Conclusions: This study establishes the noninferiority of regadenoson CTP to SPECT for
detecting or excluding myocardial ischemia.
ª 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction 2. MethodsMyocardial perfusion imaging (MPI) is an integral component
for the diagnosis and management of patients with coronary
artery disease (CAD). Single photon emission CT (SPECT) is the
most frequently requested and widely available noninvasive
MPI modality. Importantly, it provides an accurate assess-
ment of the presence or absence of myocardial ischemia and
infarction, yields incremental prognostic information, and
contributes to therapeutic decision making.1e6
Coronary CT angiography (CTA) is a noninvasive procedure
with high diagnostic performance for the detection and
exclusion of obstructive coronary stenosis.7e10 Although CTA
offers high sensitivity and negative predictive value, its
specificity and positive predictive value are less robust and
indicate a systematic overestimation of stenosis severity.11e13
Furthermore, even for high-grade stenoses correctly identified
by CTA, comparison with a fractional flow reserve or SPECT
reference standard indicates that more than half do not cause
ischemia.13,14 These findings have evoked concerns that CTA
without adjunctive physiologic data may promote excess
referral to invasive angiography and/or revascularization.
Stress myocardial CT perfusion (CTP) provides a combined
assessment of both cardiac anatomy and physiology. Multiple
single-center studies have established its feasibility using
stress agents such as adenosine and dipyridamole, with
similar diagnostic accuracy compared with other techniques,
including SPECT, fractional flow reserve, cardiac magnetic
resonance imaging, and invasive coronary angiography.15e22
To date, however, the diagnostic performance of rega-
denoson CTP has not been tested in a prospective, multi-
center study. Moreover, all prior investigations have been
confined to single CT scanner vendors. Thus, the hypothesis
of this multicenter, multivendor phase 2 trial is to evaluate
whether regadenoson CTP is noninferior to regadeno-
son SPECT for the detection or exclusion of myocardial
ischemia.This phase 2, open-label, randomized, crossover study was
conducted at 11 centers in the United States using 6 different
CT scanners (including 64-, 128-, 256-, and 320-slice systems;
ClinicalTrials.gov: NCT01334918). Of important note, 5 of the
11 participant sites had limited experience with stress CTP.
The study design and methodology have been previously
described in detail23 and are outlined here. The study was
conducted in compliance with the principles of the Declara-
tion of Helsinki, International Conference on Harmonisation
of Technical Requirements for Registration of Pharmaceuti-
cals for Human Use, and Good Clinical Practice. The institu-
tional review board or independent ethics committee of each
study center approved the protocol and consent form. Each
participant provided written informed consent before any
study-related procedures.
2.1. Subjects and randomization
Detailed inclusion and exclusion criteria have been published
previously.23 In summary, the study included symptomatic
men aged 45 years and women aged 50 years with a sus-
picion or known diagnosis of CAD who had been referred for
anMPI or cardiac CT procedure. Subjectswere excluded if they
had renal dysfunction (glomerular filtration rate<45mL/min),
were pregnant or lactating, had history of second- or third-
degree heart block or sinus node dysfunction (unless the
subject had a functioning pacemaker), symptomatic hypo-
tension, allergy to study drugs, atrial fibrillation or significant
arrhythmias, or contraindications to b-blockers.
On study day 1, subjects were randomized to 1 of 2 imaging
procedure sequences. Subjects allocated to imaging procedure
sequence 1 had a rest SPECT scan followed by a regadenoson-
stress SPECT scan on day 1, then a regadenoson-stress CTP
scan and a rest CTP (and CTA, same acquisition) scan on day 2.
Subjects allocated to imaging procedure sequence 2 had a
J o u rn a l o f C a r d i o v a s c u l a r C om p u t e d T omog r a p h y 9 ( 2 0 1 5 ) 1 0 3e1 1 2 105regadenoson-stress CTP scan and a rest CTP (and CTA) scan
on day 1, then a rest SPECT scan and a regadenoson-stress
SPECT scan on day 2.
The efficacy analysis set included all randomized subjects
with interpretable SPECT and CTP scans as determined by at
least 2 of the 3 blinded readers. The safety analysis set
included all randomized subjects who received at least 1 dose
of regadenoson.
2.2. Myocardial perfusion imaging
Regadenoson was used as the stress agent for both the
SPECT and CTP imaging procedures. At least 24 hours were
required between each dose of regadenoson. Subjects’
symptoms, heart rates, blood pressures, and electrocardio-
grams (ECGs) were closely monitored throughout the imag-
ing procedures.
2.2.1. SPECT imaging
All SPECT MPI procedures were performed as previously
described23 and according to the American Society of Nuclear
Cardiology guidelines.24 The rest scan was performed before
the stress scan for protocol consistency across the study
sites.
Rest scans were performed 60 (10) minutes after the
administration of 10 to 12 mCi of a technetium-99mebased
radiotracer (sestamibi or tetrofosmin).
For the stress scan, regadenoson was administered as a
single bolus injection delivered over 10 seconds via an intra-
venous (IV) catheter, followed immediately by a 5-mL saline
flush. The radiotracer (dose according to investigator discre-
tion or site standard of care) was administered 10 to 20 sec-
onds after the saline flush, and stress SPECT scans were
performed 60 (10) minutes after radiotracer administration.
2.2.2. CTP imaging
For CTP procedures, the stress scan was performed before the
rest scan to avoid potential contamination of delayed contrast
from the rest scan into the stress scan. The CTP imaging
protocol, including scanner-specific information, has been
previously described in detail.23 In summary, the following
principles weremaintained across scanner platforms: (1) real-
time bolus tracking was implemented to trigger the onset of
imaging; (2) prospective ECG triggering was used when
adequate heart rate control was maintained; (3) when retro-
spective ECG gating was required (because of higher heart
rates), tube current modulation was used, with peak current
from 40% to 80% of the R-R interval for stress CTP and 10% of
mid-diastole for rest CTP; and (4) tube voltage and current
were adjusted according to body mass index with 100 kV used
for smaller subjects.
Just before the stress scan, subjects with a heart rate of65
beats/min and blood pressure>100/60mmHgwere given oral
metoprolol 50 to 100 mg. Regadenoson was administered as a
single bolus injection delivered over 10 seconds via an IV
catheter, followed immediately by a 5-mL saline flush.
Approximately 1 minute after regadenoson administration,
the subject’s heart rate was obtained to update the scanner
parameters (for retrospective ECG gating in general when
heart rate >65 beats/min, or prospective ECG triggering ifheart rate was 65 beats/min). Provided that the subject was
deemed stable, 50 to 75 mL (depending on scanner platform
and subject size) of iodinated contrast was administered into
the same catheter no later than 1.5minutes after regadenoson
administration, with images acquired no later than 2 minutes
after regadenoson administration while the subject per-
formed a breathhold.
The rest CTP and CTA scans (same acquisition) were
performed at least 30 minutes after the stress CTP scan,
allowing for any regadenoson-related symptoms to resolve
and the subject’s heart rate to return to within 10 beats/min
of baseline. Just before the rest scan, if the subject’s heart
rate remained elevated, IV metoprolol 5 mg was adminis-
tered every 3 to 5 minutes (up to 20 mg). Sublingual nitro-
glycerin 0.4 mg was administered 3 minutes before image
acquisition to achieve coronary vasodilation. A second 50- to
75-mL (depending on scanner platform and subject size)
bolus of iodinated contrast was then administered (with the
total dose for the stress and rest procedures not to exceed 150
mL) and images acquired while the subject performed a
breathhold.
2.2.3. Imaging data interpretation
Reconstructed image data were transferred from all sites to a
core laboratory for processing and analysis. Images were
evaluated by 3 independent blinded expert readers for each
modality.
Using parallel methods in the SPECT and CTP core labora-
tories and the American College of Cardiology/American
Heart Association 17-segment model for standardized
myocardial segmentation25 with exclusion of the apex, each
segment was scored for perfusion defect severity using a
semiquantitative scoring system (0 ¼ normal perfusion;
1 ¼mild reduction in counts or mild reduction in attenuation
<1/3 transmurality, not definitively abnormal; 2 ¼ moderate
reduction in counts or moderate reduction in attenuation
>1/3 to <50% transmurality, definitely abnormal; 3 ¼ severe
reduction in counts or severe reduction in attenuation >50%
transmurality; 4 ¼ absent uptake or absent perfusion with
myocardial thinning). For each of the 17 segments, both fixed
and reversible defects were identified, and the total number of
each calculated for each subject. The number of reversible
defects was calculated as the number of segments with pos-
itive differences (stress score rest score) for segments with a
stress score>1. A subject was determined to be ischemic if 2
segments had reversible defects according to the median
count across the 3 readers. If the segment was scored >1 and
was equal at both rest and stress, the segment was counted as
having a fixed defect. A subject was determined to have the
presence of fixed defects if 1 segment had a fixed defect
according to the median count across the 3 readers.
Coronary CTA analysiswas performed at least 30 days after
the CTP review by 2 of the CTP readers. Readers were blinded
to the SPECT and stress CTP images and results. All coronary
segments with a diameter>1.5mmwere analyzed for percent
stenosis using an 18-segment model, following the Society of
Cardiovascular Computed Tomography guidelines,26 and a
categorical scale (0%, 1%e24%, 25%e49%, 50%e69%, 70%e99%,
100%).26,27 Differences in assessments between the readers
were resolved by consensus.
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Adverse events were collected immediately after the first dose
of regadenoson through the day 3 follow-up, and serious
adverse events were collected through the day 30 follow-up.
The incidence of adverse events observed from the time of
regadenoson administration to 24 hours after regadenoson
administration within each modality was summarized by
modality.
Radiation exposure was examined in all subjects who
completed rest and stress scans for each modality. For CT,
radiation dose was estimated from the dose-length product
reported by each scanner and converted to whole body
effective dose using the factor k ¼ 0.014 mSv/mGy$cm. For
SPECT, whole body effective dose was estimated using the
administered radiopharmaceutical dose and themethodology
of International Commission on Radiological Protection (ICRP-
80). Specifically, the administered activity millicuries was
converted to an estimated whole body effective dose (in mSv)
using a factor of 0.285mSv/mCi of Tc99-sestamibi and a factor
of 0.23 mSv/mCi of Tc99-tetrofosmin.28,29
2.4. Variables
The primary variable was the median count (across the 3 in-
dependent blinded expert readers) of the number of segments
with reversible defects detected by SPECT and CTP, catego-
rized as absence (0e1 segments) or presence (2 segments) of
ischemia.
Secondary variables include the absence (0) or presence
(1) of fixed defects as detected by SPECT and CTP. The
absence (0e1) or presence (2) of reversible defects detectedby
SPECT was also compared with CTA (<50% or 50% stenosis).
2.5. Statistical methodology
As previously described,23 the sample size calculation deter-
mined that 88 subjects imaged with CTP and SPECT would
provide 80% power to demonstrate noninferiority of CTP
compared with SPECT in terms of detecting the presence
(0e1 reversible defect) or absence (2 reversible defects) of
ischemia using a 1-sided a level of 0.025.
Continuous variables were summarized with descriptive
statistics. Discrete variables were summarized by number
and/or percentage of subjects in each category.
With SPECT as the reference standard, agreement rates
were calculated as the average of true-positive results divided
by the total number of true-positive and false-negative results
plus true-negative results divided by the total number of true-
negative results and false-positive results. On the basis of the
pivotal regadenoson studies,30,31 the agreement rate between
the 2 modalities was estimated to be 0.78, on the basis of
the dichotomous classification of presence or absence of
ischemia. A 0.15 margin corresponded to noninferiority
boundaries of 0.63 and 0.93. As such, if the lower boundary of
the 95% confidence interval (CI) for the primary variable was
0.63, regadenoson-stress CTP would be determined to be
noninferior to SPECT.
Negative predictive values were calculated as the number
of true-negative results divided by the total number of true-negative and false-negative results, whereas positive predic-
tive values were calculated as the number of true-positive
results divided by the total number of true-positive and
false-positive results. Prevalence was calculated as the num-
ber of true-positive results plus false-negative results divided
by the total number of subjects. Analysis of negative predic-
tive values, positive predictive values, and prevalence were all
conducted post hoc.
Sensitivity was calculated as the number of true-positive
results divided by the total number of true-positive and
false-negative results, and specificity as the number of true-
negative results divided by the total number of true-negative
and false-positive results using SPECT as the reference
standard.
A receiver operating characteristic plot (post hoc analysis)
was constructed with summed difference score by CTP and
presence or absence of ischemia (2 or 0e1 reversible defects)
by SPECT. The area under the curve and associated 95% CIs
were calculated, and the optimal cutoff point determined
according to the maximum sum of sensitivity and specificity.
A post hoc analysis of the diagnostic accuracy of regade-
noson CTP vs CTA alone (<50% or 50% and 70% or 70%
stenosis) with SPECT as the reference standard was conduct-
ed, the statistical significance of which was tested using an
extendedMcNemar test.32 Diagnostic accuracywas calculated
as the number of true-positive results plus true-negative
results divided by the total number of subjects. A post hoc
summary of diagnostic performance and effective radiation
dose by site experience and CT scanner was also done.
A post hoc analysis of the inter-rater agreement including
95% CIs between each reader pair for each modality was
performed. Inter-rater agreement was calculated as the
number of subjects who were classified exactly the same for
each category of number of defects divided by the total
number of subjects.3. Results
3.1. Subjects
Of 124 subjects randomized, 110 comprised the efficacy
analysis set (Fig. 1). Most subjects were white males (Table 1),
and the mean age was 61.6  9.3 years. A total of 39% of
subjects had a history of CAD, and other comorbid conditions
were commonplace, with the most frequently observed being
hypertension and hyperlipidemia (Table 1). The number of
subjects at each site is available in Supplementary Table 1.
3.2. Efficacy
Example images are presented in Figure 2.
The primary analysis demonstrated that regadenoson CTP
was noninferior to SPECT for detecting or excluding ischemia
(2 or 0e1 reversible defects, respectively), with an agreement
rate of 0.87 (95% CI, 0.77e0.97; Table 2). The sensitivity and
specificity of regadenoson CTP to detect or exclude ischemia
were 0.90 (95% CI, 0.71e1.00) and 0.84 (95% CI, 0.77e0.91),
respectively (Table 2). Sixteen false-positive results by CTP
were compared with SPECT for the detection of reversible
Fig. 1 e Subject disposition.
*Scan nonevaluable or considered to be of poor quality by at
least 2 of the 3 blinded readers. CTP, CT perfusion; SPECT,
single photon emission CT.
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stenosis (>70%), 5 had moderate stenosis (50%e69%), and 1
had nonobstructive disease (<50%) by CTA; 2 more subjects
had nonevaluable CTAs. When the summed stress score was
categorized as normal or equivocal (0e3), mildly abnormalTable 1 e Subject demographics (safety analysis set).
Parameter Subjects, n (%)*
Sex
Male 85 (72.0)
Female 33 (28.0)
Ethnicity
Non-Hispanic or Latino 78 (66.1)
Hispanic or Latino 40 (33.9)
Race
White 106 (89.8)
Black or African American 7 (5.9)
Asian 5 (4.2)
Age (y), mean  SD 61.6  9.3
Weight (kg), mean  SD 87.3  18.6
Body mass index (kg/m2), mean  SD 29.5  5.3
Medical/surgical historyy
Hypertension 82 (69.5)
Hyperlipidemia 51 (43.2)
Coronary artery disease 46 (39.0)
Angina pectoris 41 (34.7)
Dyslipidemia 33 (28.0)
Myocardial infarction 24 (20.3)
SD, standard deviation.
* Unless otherwise stated.
y With >20% incidence.(4e7), moderately abnormal (8e11), and severely abnormal
(12), the overall agreement rate comparing CTP to SPECT for
these categories was 0.63  0.046.
The agreement rate for the detection of 1 fixed defects by
regadenoson CTP and SPECT was 0.86 (95% CI, 0.74e0.98), and
the sensitivity and specificity were 0.77 (95% CI, 0.54e1.00) and
0.95 (95% CI, 0.90e0.99), respectively (Table 3). When the
summed rest score was categorized as normal or equivocal
(0e3), mildly abnormal (4e7), moderately abnormal (8e11),
and severely abnormal (12), the overall agreement rate
comparing CTP to SPECT for these categories was 0.76  0.041.
Supplementary Table 2 describes the combined analysis of
fixed and reversible defects detected by regadenoson CTP and
SPECT.
Receiver operating characteristic analysis demonstrated
high diagnostic accuracy of CTP summed difference score to
detect or exclude ischemia (2 or 0e1 reversible defects,
respectively), with an area under the curve ( confidence in-
terval) of 0.93 (95% CI, 0.87e0.99; Fig. 3). The optimal summed
difference score cutoff of 2 reversible defects yielded a
sensitivity of 0.90 and a specificity of 0.93.
When the absence (0e1) or presence (2) of reversible
defects detected by SPECT was compared with CTA (<50% or
50% stenosis), the agreement rate was 0.83 (95% CI,
0.78e0.87) and was similar to the agreement rate when
compared with CTP (Table 4). Post hoc analysis demonstrated
that the diagnostic accuracies for detecting or excluding
ischemia by regadenoson CTP alone and CTA alone (50% or
<50% stenosis) with SPECT as the reference standard were
0.85 (95% CI, 0.78e0.92) and 0.69 (95% CI, 0.60e0.78), respec-
tively; the overall P value (P < .001) indicated CTP significantly
improved diagnostic accuracy vs CTA and was driven pri-
marily by specificity (P < .001). Results for comparisons with
CTA (<70% or 70% stenosis) and SPECT are summarized in
Table 5. The diagnostic accuracy was 0.81 (95% CI, 0.73e0.89)
and the agreement rate was 0.81 (95% CI, 0.68e0.94).
The inter-rater agreement for CTP between readers 1 and 2,
1 and 3, and 2 and 3 for reversible perfusion defects was 0.77
(0.69e0.85), 0.84 (0.77e0.91), and 0.80 (0.72e0.88), respectively,
and for fixed perfusion defects was 0.72 (0.63e0.81), 0.86
(0.79e0.92), and 0.74 (0.66e0.83), respectively. The inter-rater
agreement for SPECT between readers 1 and 2, 1 and 3, and
2 and 3 for reversible perfusion defects was 0.92 (0.86e0.97),
0.91 (0.85e0.96), and 0.95 (0.91e0.99), respectively, and for
fixed perfusion defects was 0.96 (0.93e1.00), 0.95 (0.91e0.99),
and 0.97 (0.94e1.00), respectively.
Diagnostic performance and effective radiation dose by
site experience and CT scanner platform are summarized in
Supplementary Table 3.
3.3. Safety
A total of 69% (81 of 118) subjects experienced an adverse
event, most of which were considered mild (43.2% [51 of 118]).
The incidence of adverse events within 24 hours of the last
dose of regadenoson was similar between the treatment
modalities (45.3% for SPECT and 50.9% for CTP; Table 6). Four
subjects experienced severe adverse events that were
considered probably or possibly related to regadenoson
(angina pectoris, dyspnea, jaw pain, and vomiting). Two
Fig. 2 e Example images. Example images from a 69-year-old male patient presenting with chest pain. Coronary CTA
demonstrates stenoses of>50% severity in all 3 vessels (A). CTP shows a large-sized, severe, partially reversible defect in the
mid-to-apical anterior wall, apical wall, apical septal wall, and apical lateral wall (B). SPECT shows a moderate sized, mild to
moderate severity, partially reversible defect in themid-to-apical anteriorwall, apicalwall, and apical lateralwall (C). CTA, CT
angiography; CTP, CT perfusion; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery;
SPECT, single photon emission CT. Arrows demonstrate an area of inducible ischemia in the anterior wall (LAD distribution).
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Table 2 e Number of reversible perfusion defects detected
by regadenoson CTP and SPECT (per-patient analysis).
Number of
reversible defects
Regadenoson SPECT
(reference standard)
Condition
positive (2)
Condition
negative (0e1)
All
Regadenoson CTP test outcome
Test outcome
positive (2)
9 (true positive) 16 (false positive) 25
Test outcome
negative (0e1)
1 (false negative) 84 (true negative) 85
All 10 100 110
Agreement rate 
SE (95% CI)
0.87  0.051 (0.77e0.97)
Specificity  SE
(95% CI)
0.84  0.037 (0.77e0.91)
Sensitivity  SE
(95% CI)
0.90  0.095 (0.71e1.00)
Negative predictive
value (95% CI)
0.99 (0.97e1.00)
Positive predictive
value (95% CI)
0.36 (0.17e0.55)
Prevalence (95% CI) 0.09 (0.04e0.14)
Diagnostic accuracy
(95% CI)
0.85 (0.78e0.92)
CI, confidence interval; CTP, CT perfusion; SE, standard error; SPECT,
single photon emission CT.
Table 3 e Number of fixed perfusion defects detected by
regadenoson CTP and SPECT.
Number of
fixed defects
Regadenoson SPECT
(reference standard)
Condition
positive (1)
Condition
negative (0)
All
Regadenoson CTP test outcome
Test outcome
positive (1)
10 (true positive) 5 (false positive) 15
Test outcome
negative (0)
3 (false negative) 92 (true negative) 95
All 13 97 110
Agreement rate 
SE (95% CI)
0.86  0.059 (0.74e0.98)
Specificity  SE
(95% CI)
0.95  0.022 (0.90e0.99)
Sensitivity  SE
(95% CI)
0.77  0.117 (0.54e1.00)
Negative predictive
value (95% CI)
0.97 (0.94e1.00)
Positive predictive
value (95% CI)
0.67 (0.43e0.91)
Prevalence (95% CI) 0.12 (0.06e0.18)
Diagnostic accuracy
(95% CI)
0.93 (0.88e0.98)
CI, confidence interval; CTP, CT perfusion; SE, standard error;
SPECT, single photon emission CT.
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discontinuation from the study (gastritis [within 24 hours of
regadenoson administration] and uncontrolled hyperglyce-
mia [>24 hours after regadenoson administration]); neither
event was considered to be regadenoson-related. Other than
the subject with gastritis, no other serious adverse events
were reported within 24 hours after regadenoson adminis-
tration. No deaths were reported.
Four subjects had a systolic blood pressure <90 mm Hg, 1
of whom was successfully treated with aminophylline. One
subject had a diastolic blood pressure >200 mm Hg; the sub-
ject did not receive treatment and the blood pressure returned
to normal by 60 minutes after regadenoson administration.
One subject experienced ventricular tachycardia 2 minutes
after regadenoson administration that lasted 1minute and did
not require intervention.
The total mean ( standard deviation) radiation dose was
significantly higher for regadenoson CTP (17.7  6.8 mSv)
compared with regadenoson SPECT (11.2  1.8 mSv; P ¼ .001).Fig. 3 e Receiver operating characteristic plot describing
the diagnostic performance for CTP summed difference
score to detect ‡2 reversible defects as determined by
SPECT. CTP, CT perfusion; SPECT, single photon
emission CT.4. Discussion
This is the first study demonstrating the diagnostic accuracy
of regadenoson CTP compared with regadenoson SPECT in a
multicenter, multivendor trial. Consistent with the findings of
previous studies,15e22 this study demonstrates that both
anatomic and perfusion information can be gleaned from a
single examination, with comparable diagnostic accuracy to
regadenoson SPECT.The primary analysis of this study confirmed that
regadenoson-stress CTP was noninferior to regadenoson-
stress SPECT in detecting the presence or absence of
ischemia (2 or 0e1 reversible defects, respectively) with high
agreement rate (0.87 [95% CI, 0.77e0.97]). Moreover, the
agreement rate for the detection of 1 fixed defects by
Table 4 e Numbers of coronary stenoses detected by CTA
(<50% or ‡50% stenosis) as compared with reversible
defects detected by regadenoson SPECT.
Number of
perfusion defects
Regadenoson SPECT
(reference standard)
Condition
positive (2)
Condition
negative (0e1)
All
CTA test outcome
Test outcome
positive (50%)
10 (true positive) 33 (false positive) 43
Test outcome
negative (<50%)
0 (false negative) 62 (true negative) 62
All 10 95 105
Agreement rate 
SE (95% CI)
0.83  0.024 (0.78e0.87)
Specificity  SE
(95% CI)
0.65  0.049 (0.56e0.75)
Sensitivity  SE
(95% CI)
1.00  0.000 (1.00e1.00)
Negative predictive
value (95% CI)
1.00 (1.00e1.00)
Positive predictive
value (95% CI)
0.23 (0.10e0.36)
Prevalence (95% CI) 0.10 (0.04e0.16)
Diagnostic accuracy
(95% CI)
0.69 (0.60e0.78)
CI, confidence interval; CTA, coronary CT angiography; SE, stan-
dard error; SPECT, single photon emission CT.
Table 5 e Numbers of coronary stenoses detected by CTA
(<70% or ‡70% stenosis) as compared with reversible
defects detected by regadenoson SPECT.
Number of
perfusion defects
Regadenoson SPECT
(reference standard)
Condition
positive (2)
Condition
negative (0e1)
All
CTA test outcome
Test outcome
positive (70%)
8 (true positive) 18 (false positive) 26
Test outcome
negative (<70%)
2 (false negative) 77 (true negative) 79
All 10 95 105
Agreement rate 
SE (95% CI)
0.81  0.066 (0.68e0.94)
Specificity  SE
(95% CI)
0.81  0.040 (0.73e0.89)
Sensitivity  SE
(95% CI)
0.80  0.126 (0.55e1.00)
Negative predictive
value (95% CI)
0.97 (0.93e1.00)
Positive predictive
value (95% CI)
0.31 (0.13e0.49)
Prevalence (95% CI) 0.10 (0.04e0.16)
Diagnostic accuracy
(95% CI)
0.81 (0.73e0.89)
CI, confidence interval; CTA, coronary CT angiography; SE, stan-
dard error; SPECT, single photon emission CT.
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0.74e0.98). As such, these results demonstrate that regade-
noson CTP can detect or exclude myocardial ischemia
(reversible defects) and myocardial infarct (fixed defects) with
similar diagnostic performance to SPECT.
Further analyses demonstrated that regadenoson CTP had
a significantly higher diagnostic accuracy to detectmyocardial
ischemia compared with CTA alone (with SPECT as the
reference standard). This finding confirms prior results that
stress CTP can provide incremental value to CTA alone in
improving the diagnostic accuracy to detect hemodynami-
cally significant stenosis.15e22 The combined evaluation of
stress CTP (physiology) and CTA (anatomy) in a single setting
is attractive for certain patient populations, particularly in
patientswhere guidance to define the best therapeutic options
are needed, or in patients presenting with intermediate or
borderline coronary stenoses by coronary CTA where, histor-
ically, further downstream functional testing may have been
required.
The CORE 320 study recently assessed the diagnostic
accuracy of adenosine-stress CTP and adenosine- or exercise-
stress SPECT for the diagnosis of obstructive CAD (50%
stenosis).33 The study demonstrated that CTP had greater
diagnostic accuracy compared with SPECT for diagnosing
obstructive CAD. Furthermore, the results of the CORE 320
study demonstrated incremental improvement in diagnostic
accuracy when adding CTP to CTA for diagnosing vessels with
hemodynamically significant stenosis.33 As such, these 2 large
multicenter trials are complementary, and the present studyfurther expands the use of stress CTP to multiple CT vendors
and to sites with limited experience in stress CTP.33
Administration of regadenoson was well tolerated in this
study. Adverse events were consistent with the known safety
and tolerability profile of regadenoson, and safety profiles
were similar for the 2 imaging modality sequences. The
increased radiation exposure of the regadenoson CTP protocol
in this trial compared with the SPECT protocol may be
attributed primarily to 3 reasons: (1) many different CT ven-
dors were used with predominant 64-slice CT technology; (2)
the stress CTP protocol required a retrospective gating
acquisition that was a conservative approach to ensure good
image quality at the expense of increased radiation dose; and
(3) this relatively obese population directly influenced radia-
tion exposure and tube settings such as kVp and mAs. It is
highly likely that regadenoson CTP radiation doses will drop
as increased use of new detectors, iterative reconstruction,
and software updates will continue to allow for radiation dose
reduction, as discussed previously.23,34
This study has some limitations. First, invasive coronary
angiography with fractional flow reserve, which currently is
considered the gold standard to detect hemodynamic signifi-
cance of a specific lesion, was not used as the reference
standard. Second, because of the relatively low number of
subjects with significant ischemia, definitive conclusions
cannot be drawn in an analysis by extent or severity of
ischemia, and limits conclusions that can be drawn from
subset analyses. Third, this study assessed myocardial
perfusion using visual and semiquantitative methods. There
Table 6 e Adverse events within 24 hours of the last dose of regadenoson.
Adverse event Subjects, n (%)
Regadenoson SPECT (n ¼ 117) Regadenoson CTP (n ¼ 116) Total (n ¼ 118)
Any event 53 (45.3) 59 (50.9) 81 (68.6)
Any severe event 2 (1.7) 4 (3.4) 5 (4.2)
Any serious event 1 (<1) 0 1 (<1)
Any event resulting in discontinuation 1 (<1) 0 1 (<1)*
Most common events
Flushing 18 (15.4) 26 (22.4) 40 (33.9)
Headache 15 (12.8) 23 (19.8) 30 (25.4)
Chest discomfort 11 (9.4) 9 (7.8) 17 (14.4)
Dizziness 11 (9.4) 6 (5.2) 16 (13.6)
Dyspnea 13 (11.1) 10 (8.6) 16 (13.6)
Angina pectoris 4 (3.4) 9 (7.8) 11 (9.3)
Nausea 9 (7.7) 6 (5.2) 11 (9.3)
CTP, myocardial CT perfusion; SPECT, single photon emission CT.
* A second subject discontinued the study after a serious adverse event of uncontrolled hyperglycemia >24 hours after regadenoson admin-
istration on the day he was to undergo the CTP procedure. The event was not considered to be regadenoson related.
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absolute terms.35 Fourth, the high prevalence of subjects with
known CAD (39%) likely resulted in a high number of falsely
positive CTA findings. At the same time, the prevalence of
myocardial ischemia was low providing an advantage for CTP.
This limits the generalizability of the study findings to other
populations. Finally, almost half of the participant sites had
limited experience with stress CTP before, and thus, accuracy
would be expected to be even higher and radiation dose lower
in sites that have more experience in acquisition of CTP.
However, the results support the fact that this technique can
be generalized and used across a wide range of sites, not just
in “expert” centers.
Future research studies should address how this combined
evaluation of stress CTP and CTA in a single setting can be
cost-effective and improve patient outcomes for specific pa-
tient populations by guiding better therapeutic options.5. Conclusion
This multicenter, multivendor study demonstrates good
diagnostic accuracy of CTP for the detection of ischemia
compared to SPECT as the reference standard. The resultsmet
the predefined noninferiority of regadenoson CTP to SPECT for
detecting or excludingmyocardial ischemia; regadenoson CTP
provides improved diagnostic accuracy over CTA alone for
detection of myocardial ischemia.
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Supplementary Table 1 e Number of subjects at each site.
Site CT machine Regadenoson
SPECT-MDCT (N ¼ 55), n (%)
Regadenoson
MDCT-SPECT (N ¼ 55), n (%)
Total (N ¼ 110)
A Siemens Definition Flash; 128  0.6 2 (3.6) 4 (7.3) 6 (5.5)
B Toshiba Aquilon ONE 320; 320  0.6 7 (12.7) 5 (9.1) 12 (10.9)
C Phillips 256 ITC; 128  0.625 7 (12.7) 4 (7.3) 11 (10.0)
D GE Lightspeed VCT 64  0.625 5 (9.1) 1 (1.8) 6 (5.5)
E GE VC 64; 64  0.625 4 (7.3) 4 (7.3) 8 (7.3)
F GE Lightspeed VCT; 64  0.625 3 (5.5) 2 (3.6) 5 (4.5)
G Phillips Brilliance 64; 64  0.625 11 (20.0) 9 (16.4) 20 (18.2)
H Phillips Brilliance 64; 64  0.625 0 1 (1.8) 1 (0.9)
I GE VCT 64; 64  0.625 6 (10.9) 14 (25.5) 20 (18.2)
J Siemens Definition 64; 64  0.6 0 1 (1.8) 1 (0.9)
K Siemens Sensation 64; 64  0.6 10 (18.2) 10 (18.2) 20 (18.2)
MDCT, multidetector computed tomography; SPECT, single photon emission CT.
Supplementary Table 2 e Number of fixed and reversible
perfusion defects detected by regadenoson CTP and
SPECT.
Number of fixed
defects or
reversible
defects (*)
Regadenoson SPECT
(reference standard)
Condition
positive
Condition
negative
All
Regadenoson CTP test outcome
Test outcome
positive
18 (true positive) 16 (false positive) 34
Test outcome
negative
2 (false negative) 74 (true negative) 76
All 20 90 110
Agreement rate 
SE (95% CI)
0.86  0.039 (0.78e0.94)
Specificity  SE
(95% CI)
0.82  0.040 (0.74e0.90)
Sensitivity  SE
(95% CI)
0.90  0.067 (0.77e1.00)
Negative predictive
value (95% CI)
0.97 (0.93e1.00)
Positive predictive
value (95% CI)
0.53 (0.36e0.70)
Prevalence (95% CI) 0.18 (0.11e0.25)
Diagnostic accuracy
(95% CI)
0.84 (0.77e0.91)
CI, confidence interval; CTP, CT perfusion; SE, standard error;
SPECT, single photon emission CT.
* Positive: 1 fixed or 2 reversible; negative: 0 fixed and 0 to 1
reversible.
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Supplementary Table 3 e Diagnostic performance and effective radiation dose by site experience and CT scanner platform.
Number of
subjects
Agreement  SE
(95% CI)
Specificity  SE
(95% CI)
Sensitivity  SE
(95% CI)
NPV (95% CI) PPV (95% CI) Prevalence
(95% CI)
Diagnostic
accuracy (95% CI)
Effective
dose (mSv),
mean (SD)
Experience
Prior experience
with CTP
70 0.91  0.024 (0.86e0.96) 0.82  0.049 (0.73e0.92) 1.00  0.000 (1.00e1.00) 1.00 (1.00e1.00) 0.42 (0.20e0.64) 0.11 (0.04e0.18) 0.84 (0.75e0.93) 17.34 (6.71)
Limited prior
experience
with CTP
40 0.68  0.179 (0.33e1.00) 0.87  0.055 (0.76e0.98) 0.50  0.354 (0.00e1.00) 0.97 (0.91e1.00) 0.17 (0.00e0.47) 0.05 (0.00e0.12) 0.85 (0.74e0.96) 18.17 (7.25)
CT model
GE Lightspeed VCT 39 0.78  0.139 (0.51e1.00) 0.89  0.052 (0.79e0.99) 0.67  0.272 (0.13e1.00) 0.97 (0.91e1.00) 0.33 (0.00e0.71) 0.08 (0.00e0.17) 0.87 (0.76e0.98) 18.41 (8.23)
Siemens Definition 7 N/A 0.86  0.132 (0.60e1.00) N/A 1.00 (1.00e1.00) 0.00 (0.00e0.00) 0.00 (0.00e0.00) 0.86 (0.60e1.00) 16.12 (10.58)
Toshiba Aquilion
ONE
12 0.94  0.058 (0.82e1.00) 0.88  0.117 (0.65e1.00) 1.00  0.000 (1.00e1.00) 1.00 (1.00e1.00) 0.80 (0.45e1.00) 0.33 (0.06e0.60) 0.92 (0.77e1.00) 15.80 (5.59)
Phillips iCT 11 0.95  0.047 (0.86e1.00) 0.90  0.095 (0.71e1.00) 1.00  0.000 (1.00e1.00) 1.00 (1.00e1.00) 0.50 (1.00e1.00) 0.09 (0.00e0.26) 0.91 (0.74e1.00) 14.30 (5.01)
Siemens Somatom
Sensation 64
20 N/A 0.90  0.067 (0.77e1.00) N/A 1.00 (1.00e1.00) 0.00 (0.00e0.00) 0.00 (0.00e0.00) 0.90 (0.77e1.00) 18.63 (4.97)
Phillips Brilliance 21 0.82  0.055 (0.71e0.92) 0.63  0.111 (0.41e0.85) 1.00  0.000 (1.00e1.00) 1.00 (1.00e1.00) 0.22 (0.00e0.49) 0.10 (0.00e0.23) 0.67 (0.47e0.87) 18.60 (5.56)
CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value; SE, standard error.
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